Financial comparisons Intellia Therapeutics, Inc.
Equities
NTLA
US45826J1051
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.94 USD | +1.08% |
|
+7.71% | +66.18% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
 | 67.67M | -609.85% | -651.67% | -61.47% | -49.01% | 1.4x | |
| 8.24B | 14.53% | 21.7% | 10.28% | 4.9% | 1.58x | |
| 5.34B | 5.37% | 8.37% | 29.84% | 16.27% | -5.99x | |
| 16.31B | 8.34% | 13.38% | 32.9% | 4.79% | 3.63x | |
| 2.88B | 24.74% | 28.07% | 5.94% | 4.75% | 2.2x | |
| 846M | -31.67% | -18.92% | - | - | 1.57x | |
| 2.53B | 17.83% | 20.93% | 70.23% | 22.13% | -0.89x | |
| 8.57B | 6.51% | 14.79% | 9.61% | 4.34% | 2.22x | |
| 944M | -40.36% | -40.47% | -70.72% | -11.67% | 4.51x | |
| 5.4M | -7,306.52% | -5,350% | -135.58% | - | 2.1x | |
| 1.22B | 6.02% | 31.45% | 15.37% | 11.65% | 0.43x | |
| 1.27B | -19.27% | -3.71% | -38.64% | -6.61% | -65.61x | |
| 4.02B | -3.59% | 19.77% | 15.46% | 6.99% | 1.98x | |
| 2.09B | 20.33% | 29.46% | 17.5% | 10.73% | 0.74x | |
| 8.28B | 9.56% | 19.29% | 12.39% | 6.87% | 1.66x | |
| 509M | -13.19% | -41.67% | -31.26% | -21.6% | -0.14x | |
| 2.02B | 11.8% | 13.68% | 11.6% | 6.52% | 1.81x | |
| Average | 3.83B | -464.67% | -346.21% | -6.66% | 0.74% | -2.75x | |
| Weighted average by Cap. | 5.55B | -259.39% | -184.16% | 5.99% | 5.55% | -1.66x |
- Stock Market
- Equities
- NTLA Stock
- Sector Intellia Therapeutics, Inc.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
